Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3645 publications

Lung Cancer in Nonsmoking Individuals: A Review.

Lung Cancer in Nonsmoking Individuals: A Review.

Journal: JAMA
Published: October 20, 2025

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

Journal: The New England journal of medicine
Published: October 17, 2025

Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC.

Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC.

Journal: Science advances
Published: October 17, 2025

Advances in Multimodality Management of Localized NSCLC.

Advances in Multimodality Management of Localized NSCLC.

Journal: Seminars in respiratory and critical care medicine
Published: October 03, 2025

Integrated Machine Learning and Structure-Based Virtual Screening Identify Osimertinib as a TNIK Inhibitor for Idiopathic Pulmonary Fibrosis.

Integrated Machine Learning and Structure-Based Virtual Screening Identify Osimertinib as a TNIK Inhibitor for Idiopathic Pulmonary Fibrosis.

Journal: Journal of chemical information and modeling
Published: September 26, 2025

Loss of tumor suppressor circRNA CircSPINT2 drives osimertinib resistance in lung adenocarcinoma.

Loss of tumor suppressor circRNA CircSPINT2 drives osimertinib resistance in lung adenocarcinoma.

Journal: Molecular therapy. Oncology
Published: September 25, 2025

Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity.

Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity.

Journal: Journal for immunotherapy of cancer
Published: September 22, 2025

Unresectable stage III non-small-cell lung cancer: state of the art and challenges.

Unresectable stage III non-small-cell lung cancer: state of the art and challenges.

Journal: Nature reviews. Clinical oncology
Published: September 15, 2025

Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.

Anaplastic Lymphoma Kinase (ALK) Fusion as a Resistance Mechanism to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors With Complete Response After Osimertinib and Alectinib: A Case Report and Literature Review.

Journal: Cureus
Published: September 13, 2025

Research Progress on the Regulation of Third-generation EGFR-TKIs Resistance 
in Non-small Cell Lung Cancer by Redox Homeostasis

Research Progress on the Regulation of Third-generation EGFR-TKIs Resistance 
in Non-small Cell Lung Cancer by Redox Homeostasis

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: September 11, 2025

A novel biguanide-derivative promotes NEDD4-mediated FGFR1 ubiquitination through BMI1 to overcome osimertinib resistance in NSCLC.

A novel biguanide-derivative promotes NEDD4-mediated FGFR1 ubiquitination through BMI1 to overcome osimertinib resistance in NSCLC.

Journal: Cancer biology & medicine
Published: September 11, 2025

Identification of Targetable EGFR Mutations in Ovarian Cancer.

Identification of Targetable EGFR Mutations in Ovarian Cancer.

Journal: JCO precision oncology
Published: September 10, 2025
Showing 1-12 of 3,645

Last Updated: 10/31/2025